12 completed, 6 unknown, 3 terminated, 2 recruiting. 26 Phase 2, 6 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 26 | Completed 12, Unknown 6, Terminated 3, Recruiting 2, Active not recruiting 1, Not yet recruiting 1, Withdrawn 1 |
| Phase 1 | 6 | Completed 3, Terminated 2, Unknown 1 |
Follow Drug Evaluation: new trials by email Literature Review of Drug Evaluation trials Research Report on Drug Evaluation
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Clinical Trial of GRT7040 in Adults With Acute Pain Following Bunionectomy GRT7040, Hydrocodone bitartrate/ acetaminophen (HB/APAP), Placebo (matched to HB/APAP) - Acute Pain, Bunionectomy | Phase 2 | Not yet recruiting | Grünenthal GmbH | 400 | 2026-09-01 | 2026-09-15 |
| SC0191 Plus Chemotherapy in Advanced Ovarian Canceradvanced Ovarian Cancer SC0191, Gemcitabine, Paclitaxel - Serous Ovarian Cancer, Advanced Ovarian Cancer | Phase 1 / Phase 2 | Unknown | Biocity Biopharmaceutics Co., Ltd. | 112 | 2023-10-30 | 2023-09-26 |
| Pre-diltiazem, Calcium Versus Placebo for Atrial Fibrillation With Rapid Ventricular Response Placebo, Calcium - Atrial Fibrillation With Rapid Ventricular Response, Hypotension | Phase 2 | Unknown | Ascension Health | 378 | 2023-01-26 | 2023-01-20 |
| Study of the ZN-d5 and ZN-c3 in Subjects With Acute Myeloid Leukemia (AML) ZN-d5 ZN-c3, ZN-c3 - Acute Myeloid Leukemia (AML) | Phase 1 / Phase 2 | Terminated | K-Group Alpha, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc. | 40 | 2022-12-01 | 2024-09-19 |
| Phase 1/2 Study of ZN-d5 for the Treatment of Relapsed or Refractory Light Chain (AL) Amyloidosis ZN-d5 - Amyloidosis, AL Amyloidosis | Phase 1 / Phase 2 | Completed | K-Group Alpha, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc. | 18 | 2021-11-30 | 2024-09-19 |
| Testosterone Replacement in Male Cancer Survivors With Fatigue and Low Testosterone Testosterone Undecanoate 750 MG/3 ML Intramuscular Solution [AVEED], placebo - Hypogonadism, Male, Fatigue Syndrome, Chronic | Phase 2 | Recruiting | Seattle Institute for Biomedical and Clinical Research | 240 | 2021-03-22 | 2026-06-22 |
| Study of the Apatinib Combine With POF Versus POF in Gastric Cancer Apatinib, POF - Gastric Adenocarcinoma, Advanced Cancer | Phase 2 | Unknown | Fujian Cancer Hospital | 116 | 2019-12-01 | 2019-10-09 |
| Pyrotinib Combined With Trastuzumab Plus Aromatase Inhibitor in Treatment of Breast Cancer Pyrotinib, Trastuzumab, Aromatase Inhibitors - Breast Cancer Female, HER2-positive Breast Cancer | Phase 2 | Unknown | Fuzhou General Hospital | 77 | 2019-11-01 | 2019-09-12 |
| Pyrotinib Combined With Trastuzumab and AI in the First-line Treatment of HER2 Positive/ HR Positive MBC Pyrotinib, Trastuzumab, Aromatase inhibitor - Breast Cancer Female, HER2-positive Breast Cancer | Phase 2 | Unknown | Peking Union Medical College Hospital | 250 | 2019-06-01 | 2019-04-10 |
| MNK6106 for Liver Disease (Hepatic Cirrhosis) That in the Past Has Affected the Brain (Hepatic Encephalopathy) MNK6106, Rifaximin - Hepatic Cirrhosis, Hepatic Encephalopathy (HE) | Phase 2 | Completed | Mallinckrodt | 50 | 2018-12-01 | 2021-07-20 |
| A Study to Evaluate the Safety and Efficacy of CT1812 in Subjects With Mild to Moderate Alzheimer's Disease. CT1812, Placebo - Mild to Moderate Alzheimer's Disease | Phase 2 | Completed | Cognition Therapeutics | 153 | 2018-10-10 | 2025-08-11 |
| Evaluate Efficacy and Safety of X0002 in Treatment of Knee Osteoarthritis X0002 Spray, Ibuprofen Tablet, Ibuprofen Placebo Tab - KNEE OSTEOARTHRITIS | Phase 2 | Completed | Tianjin XinChen-Techfields Pharma Co., LTD. | 353 | 2018-07-16 | 2020-01-13 |
| Add-on Methotrexate for the Treatment of Schizophrenia Methotrexate, Placebo Arm - Schizophrenia | Phase 2 | Unknown | Sheba Medical Center | 100 | 2017-12-15 | 2017-12-12 |
| Progesterone to Enhance the Efficacy and Success of Expectantly Managed Preterm Severe/Superimposed Preeclampsia 17 OHPC - Pregnancy, Preeclampsia (PE) | Phase 2 | Recruiting | University of Mississippi Medical Center | 60 | 2017-05-22 | 2026-05-01 |
| A Study of AV0328 Administered to Healthy Adult Volunteers AV0328 - Cohort 1, AV0328 - Cohort 2, AV0328 - Cohort 3 - PNAG-expressing Pathogenic Microbes Vaccine | Phase 1 / Phase 2 | Completed | Alopexx Vaccine, LLC | 16 | 2017-03-22 | 2019-03-19 |
| Clinical Trial of Patidegib Gel 2%, 4%, and Vehicle Applied Once or Twice Daily to Decrease the GLI1 Biomarker in Sporadic Nodular Basal Cell Carcinomas Patidegib, Vehicle gel - Basal Cell Carcinomas | Phase 2 | Completed | PellePharm, Inc. | 36 | 2016-11-11 | 2019-01-08 |
| Clinical Trial of CT1812 in Mild to Moderate Alzheimer's Disease CT1812, Placebo - Alzheimer's Disease | Phase 1 / Phase 2 | Completed | Cognition Therapeutics | 19 | 2016-09-01 | 2018-07-26 |
| Trial of Patidegib Gel 2%, 4%, and Vehicle to Decrease the Number of Surgically Eligible Basal Cell Carcinomas in Gorlin Syndrome Patients Patidegib, Vehicle gel - Basal Cell Nevus Syndrome | Phase 2 | Completed | PellePharm, Inc. | 17 | 2016-06-06 | 2020-07-23 |
| The Ruxo-BEAT Trial in Patients With High-risk Polycythemia Vera or High-risk Essential Thrombocythemia Ruxolitinib, BAT - Polycythemia Vera (PV), Essential Thrombocythemia (ET) | Phase 2 | Active not recruiting | RWTH Aachen University | 207 | 2015-10-01 | 2026-08-13 |
| LY2157299 Monohydrate (LY2157299) and Radiotherapy in Metastatic Breast Cancer Radiation therapy, Study Drug - Metastatic Breast Cancer | Phase 2 | Terminated | Weill Medical College of Cornell University | 3 | 2015-08-10 | 2019-12-09 |
Showing 20 of 26. Sign in to see all of them.
Breast Neoplasms (3) · Alzheimer Disease (2) · Basal Cell Nevus Syndrome (2) · Breast Diseases (2) · Carcinoma, Basal Cell (2) · Schizophrenia (2) · Acute Pain (1) · Amyloidosis (1) · Atrial Fibrillation (1) · Cigarette Smoking (1) · Colorectal Neoplasms (1) · Diabetes Mellitus (1) · Diabetic Foot (1) · Eunuchism (1) · Fatigue Syndrome, Chronic (1)
Cognition Therapeutics (2) · K-Group Alpha, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc. (2) · PellePharm, Inc. (2) · Alopexx Vaccine, LLC (1) · Ascension Health (1) · Biocity Biopharmaceutics Co., Ltd. (1) · CoMentis (1) · Fujian Cancer Hospital (1) · Fuzhou General Hospital (1) · Grünenthal GmbH (1) · Kenneth Peters, MD (1) · Mallinckrodt (1) · Peking Union Medical College Hospital (1) · RWTH Aachen University (1) · Seattle Institute for Biomedical and Clinical Research (1)
United States (14) · Australia (3) · China (3) · Spain (2) · Cyprus (1) · Czechia (1) · Germany (1) · Greece (1) · Israel (1) · Italy (1) · Netherlands (1) · Puerto Rico (1) · United Kingdom (1)
Andrew Brenner, MD, (1) · Anthony Caggiano, MD (1) · Babbette LaMarca, PhD (1) · Chen Xi, PhD (1) · Elaine Weiner, M.D. (1) · Ervin Epstein, MD (1) · Hal Landy, MD (1) · Henry Hsu, MD (1) · John Lear, MD (1) · Jose M Garcia, MD, PhD (1) · Kenneth M Peters, M.D. (1) · Leslie Amass, Ph.D. (1) · Martin J Heslin, M.D. (1)
PMID 32660609, PMID 33559354, PMID 36564535, PMID 37142273, PMID 37592092, PMID 38914170, PMID 39166791, PMID 40226119, PMID 41930592, PMID 41943055
2015 (1), R01AG058660 (1), R01DA011160 (1)